Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q4 EPS of ($0.81), $0.22 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $72 thousand versus the consensus estimate of $50.92 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.